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Abstract
Background: Exposure to cigarette smoke is a major risk factor for head and neck squamous cell carcinoma (HNSCC). We
have previously established a chronic cigarette smoke extract (CSE)-treated human oral normal keratinocyte model,
demonstrating an elevated frequency of mitochondrial mutations in CSE treated cells. Using this model we further
characterized the mechanism by which chronic CSE treatment induces increased cellular proliferation.
Methodology/Principal Findings: We demonstrate that chronic CSE treatment upregulates PDK2 expression, decreases
PDH activity and thereby increases the glycolytic metabolites pyruvate and lactate. We also found that the chronic CSE
treatment enhanced HIF1a accumulation through increased pyruvate and lactate production in a manner selectively
reversible by ascorbate. Use of a HIF1a small molecule inhibitor blocked the growth induced by chronic CSE treatment in
OKF6 cells. Furthermore, chronic CSE treatment was found to increase ROS (reactive oxygen species) production, and
application of the ROS scavengers N-acetylcysteine abrogated the expression of PDK2 and HIF1a. Notably, treatment with
dichloroacetate, a PDK2 inhibitor, also decreased the HIF1a expression as well as cell proliferation in chronic CSE treated
OKF6 cells.
Conclusions/Significance: Our findings suggest that chronic CSE treatment contribute to cell growth via increased ROS
production through mitochondrial mutations, upregulation of PDK2, attenuating PDH activity thereby increasing glycolytic
metabolites, resulting in HIF1a stabilization. This study suggests a role for chronic tobacco exposure in the development of
aerobic glycolysis and normoxic HIFa activation as a part of HNSCC initiation. These data may provide insights into
development of chemopreventive strategies for smoking related cancers.
Citation: Sun W, Chang SS, Fu Y, Liu Y, Califano JA (2011) Chronic CSE Treatment Induces the Growth of Normal Oral Keratinocytes via PDK2 Upregulation,
Increased Glycolysis and HIF1a Stabilization. PLoS ONE 6(1): e16207. doi:10.1371/journal.pone.0016207
Editor: Robert E. Means, Yale Medical School, United States of America
Received August 26, 2010; Accepted December 8, 2010; Published January 19, 2011
Copyright:  2011 Sun et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study is supported by a Clinical Innovator Award from the Flight Attendant Medical Research Institute, and the National Cancer Institute SPORE
(5P50CA096784-05) and EDRN U01CA084986. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: J.A. Califano is the Director of Research of the Milton J. Dance Head and Neck Endowment. The terms of this arrangement are being
managed by the Johns Hopkins University in accordance with its conflict of interest policies. This does not alter the authors’ adherence to all the PLoS ONE
policies on sharing data and materials.
* E-mail: jcalifa@jhmi.edu
Introduction
Cigarette smoke accounts for 30% of all cancer related deaths in
the United States. Cigarette smoke has been linked to a variety of
malignancies and is an important factor that is causally associated
with HNSCC [1]. More than 100 carcinogens, mutagens, and
tumor promoters have been identified in tobacco smoke. Recently,
the relationship between mitochondrial alterations and cigarette
smoke has been investigated. It is known that mitochondrial DNA
content increase in response to cigarette smoking, and even several
decades after cigarette smoking, mitochondrial DNA content
alterations in response to cigarette smoking still persist [2].
Moreover, cigarette smoke exposure affects mitochondrial DNA
(mtDNA) mutations in buccal cells of smokers. mtDNA mutation
density was significantly higher in smokers than in non-smokers [3].
Mitochondrial defects have long been proposed to play an
important role in the development of cancer. The Warburg effect,
an increase in glycolysis that is maintained in conditions of high
oxygen tension (‘‘aerobic glycolysis’’) and gives rise to enhanced
pyruvate and lactate production, is now considered a hallmark of
cancer [4,5]. Recently, studies from Lu and colleagues suggested
that glycolytic products, like pyruvate and lactate, lead directly to
HIF1a activation; this further boosts metabolism, as well as
stimulate angiogenesis and invasiveness, and in turn confers a
growth advantage to cells [6]. Interestingly, mitochondrial
mutations, occurring with the frequencies ranging from 30% to
70%, contribute to a malignant phenotype via increased ROS, up-
regulation of Pyruvate Dehydrogenase Kinase (PDK) 2, attenu-
ating Pyruvate Dehydrogenase (PDH) activity, elevating pyruvate
and lactate production, and thereby HIF1a stabilization [7,8].
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development, we have previously established a chronic CSE-
treated oral keratinocyte model [9]. With this model, in this study,
we further characterize the association between tobacco smoke
and mitochondrial dysfunction. Here we found that chronic
tobacco exposure contributed to cell growth through increased
ROS production, upregulation of PDK2 expression, decreasing
PDH activity, elevated pyruvate and lactate production, and
ultimately HIF1a stabilization. This study provides insight into the
functional role of mitochondria in chronic tobacco smoke induced
early cellular changes during HNSCC initiation.
Materials and Methods
Preparation of Cigarette Smoke Extract (CSE)
CSE was prepared as we previously described according to a
modified Carp and Janoff method [9,10]. Research-grade
cigarettes, 2R4F, from the Kentucky Tobacco Research and
Development Center at the University of Kentucky were smoked
to 0.25 cm above the filter. 100% CSE was prepared by bubbling
smoke from one cigarette into 1 ml of PBS. Each puff was 2
seconds long at a rate 35 ml/second. This extract was then filtered
using a .22 um filter from BD biosciences filter. Each dilution was
done by volume in media. Treatment concentration was .1%.
Cells that were grown in a normal incubator that did not have any
cell lines treated with CSE are labeled as control-CTRL. The CSE
(100%) was stored in sterile Eppendorf tubes at 280 degree
Celsius.
Cell culture and reagents
Immortalized human oral keratinocytes (OKF6/TERT1) were
a generous gift from James Rheinwald at Brigham and Women’s
Hospital in Boston, MA. They retain the normal growth and
differentiation characteristics of primary human oral keratinocytes.
The cell line was expanded and passaged in keratinocyte serum-
free medium (Gibco/Invitrogen; 10725-018). This medium was
supplemented with BPE (25 ug/ml), epidermal growth factor
(0.2 ng/ml), CaCl2(0.4 mM) and 1% penicillin-streptomycin. Both
the cells treated with CSE and passaged cells were cultured in
37uC humidified air incubators with 5% CO2. All cell lines were
grown in 35 mm dishes. The components of Krebs-Henseleit
buffer were 5.5 mmol/L glucose, 1.3 mmol/L CaCl2, 1.3 mmol/
L MgCl2, 124 mmol/L NaCl, 3.5 mmol/L KCl, 1.25 mmol/L
K2HPO4, and 26.3 mmol/L NaHCO3 (pH 7.5), after bubbling
with 5% CO2 in air. Where indicated, glucose was replaced by the
indicated concentrations of agents.
Antibodies and reagents
Mouse monoclonal anti-HIF1a antibodies were purchased from
BD Biosciences. Rabbit polyclonal anti-PDK2 antibodies were
purchased from Abgent. Rabbit polyclonal anti–phosphorylated
PDH antibodies were generated from Dr. Verma’s laboratory.
Mouse monoclonal anti-PDH E1a subunit antibody and 29,79-
dichlorofluorescein diacetate (DCFH-DA) were from Invitrogen.
Dichloroacetate, N-acetylcysteine, and ascorbate were purchased
from Sigma. The HIF1a small molecule inhibitor NSC134754
was obtained from National Cancer Institute through their
Developmental Therapeutic Program.
Proliferation assay and Colony Formation Assay
We evaluated the ability of conditioned medium samples to
induce cellular proliferation by using MTT assays [7]. The
absorbance was measured at 570 nm with a SpectraMax M2e
Microplate reader purchased from Molecular Devices (Sunnyvale,
CA). Results were expressed as the mean 6 SEM of results from
replicate wells. The colony formation assay was carried out as
described previously. The number of colonies per well with a size
greater than 30 cells was counted with the Nikon SMZ1500
microscope [8].
Western blotting
Cells were lysed in radioimmunoprecipitation assay buffer
supplemented with proteinase inhibitor. Whole protein extracts
(,30 mg) were resolved on a 4% to 10% NuPAGE gel (Invitrogen),
transferred to a polyvinylidene fluoride membrane (Amersham
Biosciences), probed overnight at 4uC with the antibody against
PDK2, PDH, p-PDH, HIF1a, and actin, and then revealed using
the enhanced chemiluminescence system (Roche). Densitometry
was done using Image J software (NIH).
Measurement of lactate, glucose uptake and ATP levels
Pyruvate and lactate content in the medium was measured by
the enzymatic method using a commercially available fluores-
cence-based assay kit or using the CMA 600 Analyzer (CMA-
Microdialysis) as described previously. Cell number was deter-
mined using a Coulter particle analyzer [7,11]. Glucose in the
medium were quantitated using the amplex red glucose/glucose
oxidase kit (Invitrogen) using a standard curve prepared with serial
dilutions of RPMI medium (11 mM glucose) into glucose-free
RPMI medium, as described previously [12]. Fluorescence was
read using SpectraMax M2e Microplate reader, and results were
expressed as pmols/cell. ATP levels were assessed using an ATP
bioluminescence assay kit (Roche) [13].
Real-Time Quantitative Reverse Transcriptase-PCR
Total RNA was isolated with Trizol reagent according to the
manufacturer’s instructions, and then purified with an RNeasy Kit.
One microgram of total RNA was then reverse transcribed into
cDNA with Oligo-dT12-18 primers with the SuperScript First-
Strand Synthesis kit (Invitrogen). Real-time PCR was performed on
ABIPRISM7000SequenceDetectionSystemusingtheQuantiFast
SYBR Green PCR kit (Qiagen, Valencia, CA). The primers used
for real-time RT-PCR were available upon request. The b-actin
was used as an endogenous control for normalization of the
expression data of each gene. Each sample was run in triplicate to
ensure quantitative accuracy, and the threshold cycle numbers (Ct)
were averaged. The results were reported as fold changes (chronic
CSE treated cells versus the control untreated cells) and calculated
using 2-deltadelta(Ct) method [14,15].
ROS measurement
Intracellular ROS generation was assessed usingDCFH-DA with
the method described previously [16]. Briefly, One million cells per
reaction were washed and resuspended in prewarmed (37uC) PBS
containing 5 mmol/L CM-H2DCFDA and incubated at 37uC for
15 min to load the dye into the cells. Following the incubation, cells
were washed with prewarmed (37uC) growth medium and
resuspended in 10 mL growth medium/million cells and incubated
at 37uC for 30 min to allow for recovery and conversion of the
acetate esters. Cells were washed and resuspended in PBS +1% fetal
bovine serum and read by flow cytometry immediately.
Mitochondrial DNA sequencing
All the DNA samples were sequenced with MitoChip
version.2.0, an oligonucleotide microarray, as described previously
[8]. Briefly, the entire mtDNA.sequence was amplified in 3 long
overlapping PCR fragments, with each reaction containing 50 ng
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PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16207Figure 1. Chronic CSE treatment induced the growth in normal head and neck keratinocyte OKF6 cells. A. In vitro growth of OKF6 cells
chronically treated with CSE at the concentration of 0.1% for 7 months, compared with their control untreated cells. The mean absorbance of the
control cells at the timepoint of 24 h was set as 100% baseline, and used for data normalization and calculation. B. Colony focus assay showing
increased colony formation in the chronic CSE treated cells compared with the control untreated cells. C. Cell cycle analysis of chronic CSE treated
OKF6 cells. CTRL, control untreated OKF6 cells; CSE, chronic CSE treated OKF6 cells. Data represent mean6SD of three independent experiments.
Student’s t test showed significance between the chronic CSE treated OKF6 cells and the control untreated cells (P,0.05).
doi:10.1371/journal.pone.0016207.g001
Figure 2. Chronic CSE treatment elevated PDK2 expression, increasing PDHa phosphorylation. A, the protein levels of PDK2 were
determined 4 h after switching from culture medium to Krebs-Henseleit buffer in chronic CSE treated OKF6 cells. PDK2 were overexpressed by
2.260.1-fold in the CSE treated OKF6 cells versus its corresponding untreated cells (n=3, P,0.05). B. the growth of chronic CSE treated OKF6 cells
were significantly inhibited after treatment with 10 and/or 20 mM dichloroacetate for 48 h. Columns, means of three individual experiments; bars,
SD. DCA, dichloroacetate. *P,0.05, #P.0.05. C. western blot for PDHa and phosphorylated PDHa. Results are representative of three independent
experiments. CTRL, control untreated OKF6 cells; CSE, chronic CSE treated OKF6 cells.
doi:10.1371/journal.pone.0016207.g002
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fragmented and labeled with GeneChip DNA labeling reagent
and 30 units/ll terminal deoxynucleotidyl transferase (Affymetrix,
Santa Clara, CA). Prehybridization, hybridization, washing and
scanning of the MitoChip were performed as described in the
Affymetrix CustomSeq Resequencing protocol. All data is
MIAME compliant and the raw data has been deposited in a
MIAME compliant database (GEO, http://www.ncbi.nlm.nih.
gov/geo). The GSE accession number is -GSE24414. Since our
MitoChip resequencing data focus only on nucleotide changes,
rather than novel DNA sequences, we do not anticipate receiving
a GenBank sequence ID at this time.
Statistical analysis
Differences between experimental variables were estimated
using Student’s t test as appropriate. A probability level of 0.05 was
chosen for statistical significance. The columns in the histograms
represent the mean 6 SD of at least triplicate values from
independent experiments. All computations were done in R 2.11.1
(http://cran.r-project.org/).
Results
1. Chronic CSE treatment induced proliferation in normal
oral keratinocytes
Previously, we established a chronic tobacco smoke-exposed
minimally transformed oral keratinocyte model [9]. In this model,
OKF6 oral keratinocyte cells were chronically treated with CSE at
the concentration of 0.1% for 7 months. Here, with this chronic
CSE treated OKF6 cell model, we further characterize the growth
effects induced by tobacco smoke exposure. As shown in Figure 1A,
the chronic CSE treated OKF6 cells grew faster than the control
untreated cells and at day 3, there was a ,60% increase in the
growth over the control untreated cells (n=3, P,0.05). We then
performed standard colony formation assays on the chronic CSE
treated OKF6 cells, and found a significant increase for the
chronic CSE treated OKF6 cells when compared with the control
untreated cells (P,0.05, Figure 1B). Chronic CSE treated OKF6
cells possessed an accelerated S phase (8.660.4% vs 6.960.5%,
P,0.05) and G2-M phase (9.460.7% vs 5.661.3%, P,0.05)
compared with the control untreated cells (Figure 1C). These data
confirm that chronic tobacco smoke exposure induces accelerated
growth in normal OKF6 oral keratinocytes.
2. Chronic CSE treatment elevated PDK2 expression,
increasing PDHa phosphorylation
Recently we reported that inhibition of PDC activity via
enhanced expression of PDK2 contributes to the Warburg
metabolic and malignant phenotype in human HNSCC; and
inhibition of PDK2 lowers the phosphorylation of PDHa and
reverts the Warburg metabolic and malignant phenotype [11].
Thus, we examined whether PDK2 contributed to the growth
induced by chronic CSE treatment in OKF6 cells. As shown in
Figure 2A, elevated expression of PDK2 (2.260.1 for PDK2,
Figure 3. Chronic CSE treatment increased pyruvate and lactate production, accompany by enhanced glucose consumption and
ATP levels. A and B, the production of pyruvate and lactate in the culture buffer was measured in chronic CSE treated OKF6 cells. The cells were
allowed grown in 35 mm petri dish in 2 ml Krebs media for 6 h, and then the media were collected and assayed for concentrations of pyruvate and
lactate. C. the glucose uptake of chronic CSE treated OKF6 cells was significant increased compared with that of the control cells after 48 hour culture
in keratinocyte serum-free medium. D. the ATP level in chronic CSE treated OKF6 cells was significantly increased compared with that of the control
cells. Triplicate samples were used in each group. *P,0.05. CTRL, control untreated OKF6 cells; CSE, chronic CSE treated OKF6 cells.
doi:10.1371/journal.pone.0016207.g003
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cells compared with the control untreated cells. Further, we
observed that the growth was inhibited in chronic CSE treated
OKF6 cells after 2 days of treatment with 10 and/or 20 mM
dichloroacetate (a PDK2 small molecule inhibitor) to a greater
extent than was noted in the control untreated cells (Figure 2B).
To determine whether the dysregulation of PDH was triggered by
the PDK2 upregulation, we measured the expression of PDH and
phosphorylated-PDH (p-PDH) via western blot and determined
the ratio of p-PDHa to total PDHa [7]. The ratio of p-PDHa to
total PDHa in chronic CSE treated OKF6 cells was found
1.760.3-fold higher than that in the control untreated cells
(Figure 2C).
3. Chronic CSE treatment increased pyruvate and lactate
production, accompany by enhanced glucose
consumption and ATP levels
Given the elevated PDK2 expression and the increased ratio of
p-PDHa to total PDHa, we hypothesized that chronic CSE
treatment contributed to the growth of normal head and neck
keratinocyte via increased pyruvate and lactate production. As
shown in Figure 3A and 3B, we found significantly increased
pyruvate and lactate production in chronic CSE treated OKF6
cells compared with the corresponding control untreated cells. To
investigate whether this is accompanied by increased glucose
uptake and ATP levels, we monitored the glucose uptake and ATP
levels in the chronic CSE treated OKF6 cells. As shown in
Figure 3C, glucose uptake was significantly higher in the chronic
CSE treated OKF6 cells than that in the control untreated cells.
Further, we observed that chronic CSE treated cells displayed
increased ATP levels in comparison to the control untreated cells
(Figure 3D). Together, these data show increased aerobic
glycolysis in normal oral keratinocytes exposed to chronic CSE
treatment.
4. Chronic CSE treatment induces HIF1a accumulation via
enhanced lactate production
Cancer-specific aerobic glycolytic metabolites have been shown
to promote HIF1a activation under normoxia conditions by
interacting with the HIF prolyl hydroxylases (PHD 1–3) [14]. In
OKF6 cells, HIF1a accumulation was observed when exogenous
pyruvate or lactate was applied (Figure 4A and reference [7]). It is
also reported that the expression of HIF1a is an early event in oral
carcinogenesis [17]. Here we proposed that the chronic CSE
treatment induced HIF1a stabilization through the increased
pyruvate and lactate production. As shown in Figure 4B, HIF1a
was found 4.460.5-fold overexpressed in the chronic CSE treated
OKF6 cells versus their corresponding control untreated cells
(P,0.05). In addition, three representative HIF1a downstream
target genes, including GLUT1, ALDOC and PGK1, were found
to be upregulated in the chronic CSE treated OKF6 cells
(Figure 4C). It has been previously reported that at low
concentrations, ascorbate can selectively reverse the HIF1a
accumulation induced by pyruate and lactate production via
activation of PHDs. To investigate whether this occurs in the
chronic CSE treated cells, we treated the cells with 100 and
200 mM ascorbate for 24 hours. We found that the HIF1a
accumulation could be dramatically abolished by ascorbate
Figure 4. Chronic CSE treatment induced HIF1a accumulation via enhanced lactate production. A. HIF1a levels in OKF6 cells were
determined after 4 h of culture in glucose-free Krebs buffer containing 3 or 5 mmol/L lactate. Treatment with 3 and 5 mmol/L lactate caused HIF1a
accumulation by 1.360.1-fold and 1.960.2-fold, respectively. B. the protein levels of HIF1a were determined 4 h after switching from culture medium
to Krebs-Henseleit buffer in chronic CSE treated OKF6 cellsHIF1a was overexpressed by 4.460.5-fold in the chronic CSE treated OKF6 cells versus their
corresponding control untreated cells. C. quantitative RTPCR analysis for three HIF1a-regulated downstream genes, GLUT1, ALDOC and PGK1 in
chronic CSE treated OKF6 cells. D. Introduction of ascorbate decreased HIF1a expression in chronic CSE treated OKF6 cells. ASC, ascorbate. E. the
growth of chronic CSE treated OKF6 cells were inhibited after treatment with NSC134754, a HIF1a inhibitor. Cell growth was determined by using
MTT assay, after exposure for 48 h to 0.5 and 1 mM of NSC134754. Data are mean 6 SD values from three independent experiments. **P,0.01,
*P,0.05, #P.0.05. CTRL, control untreated OKF6 cells; CSE, chronic CSE treated OKF6 cells.
doi:10.1371/journal.pone.0016207.g004
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(Figure 4D). To address the contribution of HIF1a in the growth
promoting effect induced by chronic CSE treatment, a HIF1a
small molecule inhibitor, NSC134754, was applied to the chronic
CSE treated OKF6 cells [18]. Treatment with 0.5 and/or 1 mMo f
NSC134754 significantly inhibited the growth in OKF6 cells with
chronic CSE treatment (Figure 4E). Taken together, these data
suggest that HIF1a accumulation is a major mechanism of chronic
CSE treatment-induced growth in OKF6 cells.
5. Chronic CSE treatment increased ROS, increased PDK2
expression, and enhanced HIF1a expression
We hypothesized that chronic CSE treatment induces mito-
chondrial mutants, thereby initiating increased ROS production,
elevated glycolytic metabolism and HIF1a accumulation [7,8]. To
assess this theory, we compared the mitochondrial mutations
between CSE treated OKF6 cells and the control OKF6 cells by
mitochondrial DNA sequencing. We found 65 nonsysnomoymous
amino-changing mutations in CSE treated cells, whereas only 7
nonsynonymous amino-changing mutations in the control OKF6
cell (Table 1, MitoChip sequencing data is deposited in GEO, and
the GSE accession number -is GSE24414). Among the genes
showing nonsynonymous amino-changing mutaitons in the CSE
cells, genes such as ND2, APT6, ND6, COI, and COIII has been
linked with ROS production [7,19,20]. In consistent, as shown in
Figure 5A, we observed ,40% higher ROS yield in chronic CSE
treated OKF6 cells compared to the control untreated cells. To
investigate whether the increased ROS generation is responsible
for HIF1a accumulation, an ROS scavenger, (N-aceylcystine) was
applied to the CSE treated cells. We found that N-acetylcysteine
treatment abrogated the HIF1a expression (Figure 5B). Further,
we proposed that the increased ROS generation induced by
chronic CSE treatment contributes to HIF1a stabilization through
the upregulation of PDK2 expression. As shown in Figure 5C, in
the chronic CSE treated cells, introduction of N-acetylcystine
decreases PDK2 expression. Finally, we found that, after
treatment of the chronic CSE treated OKF6 cells with 5 mM
dicholoroacetate, a PDK2 small molecule inhibitor, the HIF1a
expression level was significantly decreased (Figure 5D).
Discussion
Cigarette smoke is a major risk factor for HNSCC development
[21,22]. In a recent study, we established a chronic CSE treated
OKF6 oral keratinocyte as a model for in vitro study of tobacco
smoke exposure induced HNSCC carcinogenesis [9]. It is
postulated that the chronic treatment of cells could best model
in vivo cigarette smoke exposure as compared to acute exposure
cell line models. With this cell line model, we showed that chronic
CSE treatment induced increased cell proliferation rate and
anchorage dependent growth, as well as elevated S phase and G2-
M phase in oral keratinocytes. We also performed anchorage-
independent assays on the chronic CSE treated OKF6 cells, but
the results revealed that these cells were not able to form colonies
(data not shown). Our data suggests that CSE is capable of
increasing proliferation in normal keratinocyte cell lines, and that
the growth characteristics represent an early functional molecular
change that set the stage for the progression to malignancy.
Recently, interest in the role of PDKs in cancer carcinogenesis
has been rekindled. The PDKs control the activity of PDC via
phosphorylation of the pyruvate dehydrogenase E1a. In HNSCC,
we previously found that inhibition of PDK reverses a metabolic
and malignant phenotype [11]. Moreover, PDK2 was found to be
overexpressed in HNSCC (unpublished data) as well as other
cancers including lung cancer [23]. Bonnet et al. have suggested
that PDK2 represents an important target for cancer therapy [24].
In this study, we showed that PDK2 expression is enhanced in the
chronic CSE treated OKF6 cells. A further confirmation of PDK2
upregulation is that the ratio of phosphoylated PDHa to total
PDHa, which is downstream of PDK2, was increased in chronic
CSE treated OKF6 cells in comparison to the control untreated
cells. Meanwhile, application of dichloroacetate to the chronic
CSE treated OKF6 cells, resulted in inhibition of cell growth
[7,24]. These findings suggested that PDK2 is aberrantly
expressed as a result of chronic tobacco exposure, and contributes
to the growth-promoting effect induced by tobacco exposure.
Lactate and pyruvate, the end products glycolysis, are
overproduced by cancer cells in the presence of oxygen. Given
the upregulation of PDK2 and increased ratio of phosphor-
PDHa/PDHa, we hypothesized that the Warburg effect is
triggered in chronic CSE treated OKF6 cells. We observed
increased pyruvate and lactate production, accompanied by
enhance glucose uptake and ATP levels, in the chronic CSE
treated OKF6 cells, suggesting that the increased glycolysis was
Table 1. Comparison of nonsynonymous amino-acid
changing mutations between CSE cells and CTRL cells.
Gene
Total counts of
nonsynonymous
amino-acid chang-
ing mutations
Representative DNA
mutations (Position,
Amino Acid Alteration)
CSE treated 65
ND1 8 C-.A (3474, T-.N);
T-.G (3665, W-.G)
ND2 6 C-.G (4825, Q-.E);
A-.T (5095, I-.F)
COI 6 A-.C (5992, T-.P);
G-.C (6241, A-.P)
COII 8 T-.C( 7 6 3 3 ,M - .T);
G-.C (7917, D-.H)
ATP6 4 A-.T (8735, M-.L);
T-.C( 8 9 9 1 ,L - .P)
COIII 4 T-.G (9458, L-.R);
C-.G (9694, L-.V)
ND3 3 T-.G (10075, L-.V);
A-.C (10315, M-.I)
ND4L 2 A-.G (10489, I-.M);
A-.G (10637, I-.S)
ND4 12 C-.G (11434, A-.G);
T-.C (12554, L-.P)
ND5 2 C-.A (12860, R-.S);
G-.A (12989, A-.T)
ND6 2 T-.A (14439, Y-.F);
A-.C (14594, I-.M)
CYTB 8 G-.C (15039, G-.R);
T-.A (15178, V-.E)
CRTL cells 7
ND1 1 A-.C (3577, N-.T)
COI 2 G-.C (6632, Y-.F);
T-.G (7240, Y-.D)
ND4L 1 T-.G (10685, V-.G)
ND5 2 C-.G (12986, L-.V);
G-.T (13202, V-.C)
CYTB 1 T-.C (14806, L-.P)
doi:10.1371/journal.pone.0016207.t001
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whether the cells use anaerobic or aerobic glycolysis for energy
production remains to be determined. The glycolytic metabolites,
such as pyruvate and lactate, have been shown to promote HIF-1
normoxic activation by interacting with the HIF prolyl hydrox-
ylases (PHD 1–3) independently [25]. Here we examined whether
altered HIF1a expression occurred in the OKF6 cells upon
chronic CSE treatment, corresponding to the increased produc-
tion of pyruvate and lactate. Our data showed that HIF1a
expression was significantly upregulated in the chronic CSE
treated OKF6 cells. Further, three downstream targets of HIF1a,
including GLUT1, ALDOC, and PGK1, showed increased
expression in the chronic CSE treated OKF6 cells compared with
the control untreated cell. In consistent with Lu et al’s study, we
showed that ascorbate treatment could abolish the accumulation
of HIF1a caused by increased pyruvate and lactate production in
the chronic CSE treated OKF6 cells [25]. Notably, use of a HIF1a
small molecule blocked the chronic CSE-induced cell growth in
OKF6 cells. These suggested that CSE exposure may induce the
growth of oral keratinocytes through constitutive activation of
HIF1a. In agreement to our data, Zhang et al. reported that
nicotine, the major component in cigarette smoke, can stimulate
HIF1 protein accumulation and HIF1a contribute to nicotine-
promoted cells invasion phenotypes in lung cancer cells [26]. It is
also noted that cigarette smoke exposure impairs angiogenesis by
inhibiting VEGF through decreased expression of HIF-1alpha in
hypoxic condition [27]. Moreover, Lin et al. found that the mean
nuclear HIF1a labeling indices increased significantly from
normal oral mucosa, through mild-, modertate-, and severe-
epithelial dysplasia to oral squamous cell carcinoma, suggesting
HIF1a is an early event in oral carcinogenesis [17]. Consistent
with this, positive HIF-1a immunostaining was also found in the
parabasal to middle third layer of the benign cervical squamous
epithelium and HIF-1a expression significantly increases in all
grades of dysplasia [28].
Interestingly, in our chronic CSE treated OKF6 cell model, we
have found that more amino acid changing mitochondrial
mutations than the control untreated cells. Our data supported
that the chronic CSE treatment may induce ROS production
through mitochondrial mutation, which in turn upregulated
PDK2 and HIF1a expression. First, increased ROS production
was observed in the chronic CSE treated OKF6 cells in
comparison to that in control cells. Second, inhibition of ROS
production by ROS scavenger N-acetylcysteine blocked PDK2
expression and HIF1a expression in chronic CSE treated OKF6
cells [19,29]. It is reported that N-acetylcysteine has been used as
an anticancer agent in preclinical models, and N-acetylcysteine
treatment of the cybrids carrying ROS-generating mitochondrial
mutants dramatically reduced the amount of ROS production
[19]. Third, inhibition of PDK2 expression with dichloroacetate
abrogated the HIF1a expression. It should be of note that no
experimental proof is provided that mitochondrial mutations
found in the paper are responsible for the altered growth rates,
ROS production, or HIF1 accumulation, and therefore additional
studies regarding this point are warranted.
In summary, the present study revealed the growth-promoting
effects induced by chronic tobacco exposure as early cellular
changes that lead to malignancy. As showed in Figure S1, we
proposed that, in human normal oral keratinocytes, tobacco
exposure induced mitochondrial mutations and increased ROS
productions, thereby sequentially facilitating upregualtion of
PDK2, attenuation of PDH activity, and subsequent increased
Figure 5. Chronic CSE treatment increased ROS, increasing PDK2 expression, resulting in enhanced HIF1a expression. A, ROS activity
was measured in triplicate with the intensity shift from a mean of 74.2 in the control cells (light gray) to a mean of 102.6 in the CSE treated OKF6 cells
(dark gary) (n=3, P,0.05) by flow cytometry. B. In chronic CSE treated OKF6 cells, introduction of ROS scavengers, N-acetylcysteine decreased HIF1a
expression. Results are representative of three independent experiments. NAC, N-acetylcysteine. C. In chronic CSE treated OKF6 cells, introduction of
ROS scavenger, N-acytylcysteine, decreased PDK2 Expression. NAC, N-acetylcysteine. The experiment was repeated twice with similar results. D. HIF1a
levels in chronic CSE treated OKF6 cells exposed to 5 mM dichloroacetate (DCA, PDK2 inhibitor) for 24 h. The experiments were performed twice
independently with similar results. CTRL, control untreated OKF6 cells; CSE, chronic CSE treated OKF6 cells.
doi:10.1371/journal.pone.0016207.g005
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tion), resulting in the HIF1a accumulation and the growth-
promoting transforming phenotype. Using the chronic CSE-
treated human oral normal keratinocyte model, the present study
demonstrates a role of chronic tobacco exposure in the induction
of aerobic glycolytis and HIF1a stabilization during HNSCC
initiation. Although the use of immortalized keratinocytes in the
model to study the chronic effect of CSE has some limitations as
these cells as not normal, we are confident that this study will
provide potentially important insights into mechanism of human
HNSCC carcinogenesis by chronic tobacco smoke.
Supporting Information
Figure S1 The proposed mechanism on chronic CSE
induced HNSCC initiation.
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